Nutritional composition comprising phospholipids for improving lipid absorption
A nutritional composition with lipid globules coated with protein and 0.5 to 20 wt.% phospholipids improves lipid absorption, addressing inefficient absorption in infant formulas and reducing malabsorption disorders by enhancing triglyceride secretion and droplet formation.
Patent Information
- Application Number
- PCT/EP2026/063322
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-09
- Filing Date
- 2026-05-07
- Publication Date
- 2026-11-12
AI Technical Summary
Existing infant formulas do not effectively mimic the lipid structure of human milk, leading to inefficient lipid absorption and potential calcium loss due to the sn-position of palmitic acid in triglycerides, which affects overall health and growth in infants.
A nutritional composition comprising lipid globules coated with protein, with a mode diameter of less than 1 pm and containing 0.5 to 20 wt.% phospholipids, is formulated to enhance lipid absorption by intestinal cells, particularly through an oil-in-water emulsion structure that includes free MFGM in the continuous phase.
The composition increases lipid absorption by intestinal cells, reducing lipid malabsorption and related disorders, such as exocrine pancreatic insufficiency and Cystic fibrosis, by enhancing triglyceride secretion and intracellular lipid droplet formation.
Abstract
Description
[0001] PHOSPHOLIPIDS FOR LIPID ABSORPTION
[0002] TECHNICAL FIELD OF THE INVENTION
[0003] The present invention pertains to nutritional compositions comprising lipids including phospholipids, such as infant milk formulae or medical nutritional compositions, which contribute to improved lipid absorption in the intestine of a human subject.
[0004] BACKGROUND OF THE INVENTION
[0005] Medical nutritional products are commonly used for the dietary management of a disease by providing nutritional supplementation or a complete diet for a patient.
[0006] Commercial infant formulas are commonly used today to provide supplemental or the sole source of nutrition early in life. These formulas comprise a range of nutrients to meet the nutritional needs of the growing infant, and typically include lipid, digestible carbohydrates, protein, vitamins, minerals, and other nutrients helpful for optimal infant growth and development. Commercial infant formulas are designed to mimic, as closely as possible, the composition and function of human milk.
[0007] Human milk lipids are known to have a distinct physical structure composed of large lipid globules with a mode diameter, based on volume, of about 4 pm existing of a triglyceride core coated by a tri-layer of phospholipid membranes, the milk fat globule membrane (MFGM). Standard infant formula’s typically have lipid droplets with a mode diameter, based on volume, of about 0.3-0.5 pm due to industrial processing procedures applied to achieve stable products, and the lipid droplets are not surrounded by MFGM but mostly by dairy proteins. Infant formula with lipid globules with an architecture more similar to the lipid globules in human milk have been described (e.g. WO2010 / 027258 or WO2010 / 027259).
[0008] Efficient lipid digestion, absorption, and utilization are critical for infant growth and development, as lipids provide approximately half of an infant’s energy need. Differences in processes relating to lipid handling between human milk and infant milk formula may contribute to distinct health outcomes.
[0009] Dietary lipids consist mostly (98%) oftriglycerides, with fatty acids esterified to stereospecific numbered (sn) positions on the glycerol backbone. Lipases commonly hydrolyze fatty acids at selective sn-positions, and the stereospecific distribution of fatty acids can therefore determine the fatty acid release profile during digestion.
[0010] Human milk comprises high levels of the fatty acid palmitic acid by weight of total fatty acids. Palmitic acid at the sn-1 ,3 position of a triglyceride will be hydrolysed by the enzyme lipase in the intestine into free palmitic acid. Free palmitic acid binds with calcium in the intestinal tract and forms insoluble “calcium soaps”, which results in the loss of calcium and fatty acids (FA) via the stool. When palmitic acid is at the sn-2 position of a triglyceride - such as in OPO (1 ,3-dioleoyl-2-palmitoylglycerol) - noinsoluble calcium soaps are formed. Therefore, the sn-position of palmitic acid of a triglyceride is important for the process of absorption of fat and calcium.
[0011] Lipolytic products include FA, monoglycerides (MAG), and lyso-phospholipids. These products are solubilized by bile and then transported across the brush border membrane for enterocytic uptake. After uptake, lipolytic products are re-synthesized into triglycerides and assembled into cytoplasmic lipid droplets (CLD; for intracellular lipid storage in the enterocytes) or downstream into chylomicrons. Chylomicrons are similar to the CLD but also include apolipoprotein B (ApoB) and are secreted through the basolateral membrane into the systemic circulation. This results in a postprandial increase in circulating lipids ( / .e. lipemia) which pacing is influenced by lipolysis and absorption rates and can influence the metabolic fate of the lipids.
[0012] The levels of CLDs in enterocytes are highly dynamic, and their formation depends on the quantity of dietary fat consumed, time after consumption, and region of the small intestine. Lipid stored in enterocyte CLDs is thought to contribute to CM secretion hours after a meal, providing a sustained supply of substrates in both postprandial and fasted periods. Therefore, the dynamic nature of enterocyte CLDs allows for a more regulated lipid delivery to circulation and attenuated postprandial lipemia.
[0013] Sun et al., 2024, ‘Regulating fat globule structure of infant formula based on MFGM to promote lipid uptake by improving lipolysis’, Food Hydrocolloids 155, 110167, describes a study of in vitro lipid adsorption in Caco-2 cells for digesta of different infant milk formula’s and human milk. The F1 infant formula comprising OPO and MFGM-coated fat globules (D433.67 pm) showed the highest triglyceride secretion and triglyceride content in the Caco-2 cells (both indicative of higher lipid absorption) and the levels were close to human milk. In Sun et al., it is stated that this observation may be explained by the presence of more fatty acids in the digesta of both human milk and F1 infant milk formula (in other words the fatty acid content of the digesta was not standardized).
[0014] WO2016163883A2 describes a method for advancing postprandial lipid absorption and / or increasing the rate of postprandial lipid absorption in a subject, comprising administering to the subject a nutritional composition comprising carbohydrates, protein, and lipid globules, wherein the protein comprises casein and the lipid globules comprise triglycerides derived from vegetable fat and phospholipids derived from non-human mammalian milk and wherein the lipid globules comprise a coating comprising the phospholipids and have a volume-weighed mode diameter from 2 to 6 pm and / or a specific surface area from 0.5 to 15 m2 / g lipid.
[0015] Li Zhixi et al., 2024, ‘Milk fat globule membrane proteins are crucial in regulating lipid digestion during simulated in vitro infant gastrointestinal digestion’ , Journal of Dairy Science 107, 7549-7563, describes that membrane proteins in MFGM influence lipolysis rates during infant digestion.Both WO2016163883A2 and Sun et al., 2024 teach that the combination of (i) milk-derived phospholipids present in the coating of (ii) relatively larger lipid globules promotes higher lipid absorption in the enterocytes of the intestine.
[0016] SUMMARY OF THE INVENTION
[0017] The present inventors utilized an in vitro 2D cell culture model to assess lipid absorption in Caco-2 cells, wherein the Caco-2 cells were grown on a Transwell insert and the cells showed several morphological and functional characteristics of enterocytes. The Caco-2 cells were incubated at the apical compartment (representing the gut lumen) with digesta derived from different infant milk formulas. The fatty acid content in the different digesta were standardized. The lipolytic products present in the digesta were absorbed and re-assembled intracellularly into CLD or chylomicrons. After 16h incubation the CLD I chylomicrons were stained with Oil Red O, microscopically imaged and their amount and size was determined. In addition, triglyceride secretion was measured at the basolateral compartment (representing the lymph and circulation).
[0018] The digesta were prepared using an in vitro digestion simulation method of a standard infant formula and a test infant formula. The test infant formula being similar to the standard infant formula, but with ‘free’ MFGM present in the continuous phase of the oil-in-water phase (i.e. not in the coating of the lipid globules). The lipid globules in both infant formula’s had a volume weighed mode diameter of about 0.3-0.5 pm.
[0019] Surprisingly it was found that ‘free’ MFGM has a beneficial effect on lipid absorption in the intestine, when standardization of the amount of fatty acids in the digesta’s is applied. Although the amount of intracellular lipid droplets was similar - the intracellular lipid droplets were larger in the Caco-2 cells exposed to the digesta of infant formula with ‘free’ MFGM. Also an increased level of triglycerides were secreted when the Caco-2 cells were incubated with the digesta of infant formula with ‘free’ MFGM. Both observations are indicative of an increased lipid absorption for nutritional compositions with MFGM present in the ‘free’ form.
[0020] Hence, the present invention pertains to a nutritional composition comprising lipid, protein, digestible carbohydrates, wherein the nutritional composition is an oil-in-water emulsion and the lipid is in the form of lipid globules and the lipid globules are coated with protein, wherein the lipid globules have a mode diameter based on volume, of less than 1 pm; and / or at most 40 vol.% of the lipid globules, based on total lipid volume, have a diameter of 2 to 12 pm, wherein the lipid comprises 0.5 to 20 wt.% phospholipids by weight of total lipid, wherein the composition is for use in increasing the lipid absorption by intestinal cells in a human subject, wherein the use is for treating, preventing or reducing the effects of lipid malabsorption and / or disease related malnutrition.Effective digestion of fat is essential for overall health, as it allows for absorption of many essential nutrients, plays an integral role in cellular and structural function, and supplies energy to the body. It requires coordination of secretory, motor, and absorptive functions. When this is dysfunctional, disorders of malabsorption can occur.
[0021] Increased lipid absorption by the intestinal cells is particularly advantageous for treating, preventing or reducing the effects of lipid malabsorption or disease related malnutrition. Examples of diseases that cause lipid malabsorption are exocrine pancreatic insufficiency, chronic pancreatitis, Cystic fibrosis, Short Bowel Syndrome, or Bile acid deficiency (Omer et al., 2024, Nutrition in Clinical Practice, ‘Fat digestion and absorption: Normal physiology and pathophysiology of malabsorption, including diagnostic testing’).
[0022] DETAILED DESCRIPTION OF THE INVENTION
[0023] A first aspect of the invention pertains to a nutritional composition comprising lipid, protein, digestible carbohydrates, wherein the nutritional composition is an oil-in-water emulsion and the lipid is in the form of lipid globules and the lipid globules are coated with protein, wherein the lipid globules have a mode diameter based on volume, of less than 1 pm; and / or at most 40 vol.% of the lipid globules, based on total lipid volume, have a diameter of 2 to 12 pm, wherein the lipid comprises 0.5 to 20 wt.% phospholipids by weight of total lipid, wherein the composition is for use in increasing the lipid absorption by intestinal cells in a human subject, wherein the use is for treating, preventing or reducing the effects of lipid malabsorption and / or disease related malnutrition.
[0024] The nutritional composition is in the form of an oil-in-water emulsion. The nutritional composition can be either a liquid nutritional composition, preferably a ready-to-drink liquid nutritional composition, or can be a powdered nutritional composition that is reconstituted to a ready-to-drink liquid nutritional composition before consumption. In both cases the oil-in-water emulsion is present in the liquid nutritional composition format.
[0025] The term ‘coating’ as used herein is meant that the outer surface layer of the lipid globules in the nutritional composition. A suitable way to determine whether protein or phospholipid is located on the surface of lipid globules is confocal laser scanning microscopy or transmission electron microscopy; see for instance Gal Her et al. (A novel infant milk formula concept: Mimicking the human milk fat globule structure, Colloids and Surfaces B: Biointerfaces, 136 (2015), 329-339).
[0026] Preferably, at least 90wt.% of the coating of the lipid globules is protein, more preferably at least 95 wt.% of the coating of the lipid globules is protein, most preferably 97-100wt.% of the coating of the lipid globules is protein.In a preferred embodiment, the invention may also be worded as a method for increasing the lipid absorption by intestinal cells in a human subject, wherein the use is for treating, preventing or reducing the effects of lipid malabsorption and / or disease related malnutrition, said method comprising administration of a nutritional composition comprising lipid, protein, digestible carbohydrates, wherein the nutritional composition is an oil-in-water emulsion and the lipid is in the form of lipid globules and the lipid globules are coated with protein, wherein the lipid globules have a mode diameter based on volume, of less than 1 pm; and / or at most 40 vol.% of the lipid globules, based on total lipid volume, have a diameter of 2 to 12 pm, wherein the lipid comprises 0.5 to 20 wt.% phospholipids by weight of total lipid.
[0027] In another preferred embodiment, the invention may also be worded as the use of lipid, protein, and digestible carbohydrates in the manufacture of a nutritional composition for increasing the lipid absorption by intestinal cells in a human subject, wherein the nutritional composition comprises lipid, protein, and digestible carbohydrates, wherein the nutritional composition is an oil-in-water emulsion and the lipid is in the form of lipid globules and the lipid globules are coated with protein, wherein the lipid globules have a mode diameter based on volume, of less than 1 pm; and / or at most 40 vol.% of the lipid globules, based on total lipid volume, have a diameterof 2 to 12 pm, wherein the lipid comprises 0.5 to 20 wt.% phospholipids by weight of total lipid, wherein the use is for treating, preventing or reducing the effects of lipid malabsorption and / or disease related malnutrition.
[0028] In yet another preferred embodiment, the invention may also be worded as the use of a nutritional composition comprising lipid, protein, digestible carbohydrates, wherein the nutritional composition is an oil-in-water emulsion and the lipid is in the form of lipid globules and the lipid globules are coated with protein, wherein the lipid globules have a mode diameter based on volume, of less than 1 pm; and / or at most 40 vol.% of the lipid globules, based on total lipid volume, have a diameter of 2 to 12 pm, wherein the lipid comprises 0.5 to 20 wt.% phospholipids by weight of total lipid for increasing the lipid absorption by intestinal cells in a human subject wherein the use is for treating, preventing or reducing the effects of lipid malabsorption and / or disease related malnutrition.
[0029] In yet even another preferred embodiment, administering a nutritional composition to human subject may be considered non-therapeutic. In those instances the invention may be worded as defined above by way of a method comprising administering a nutritional composition. For clarity, the method can also be defined as a non-therapeutic method for increasing lipid absorption by intestinal cells in a human subject.
[0030] The invention can therefore be worded as a non-therapeutic method for increasing lipid absorption by intestinal cells in a human subject, comprising administering a nutritional composition comprising lipid, protein, digestible carbohydrates, wherein the nutritional composition is an oil-in-water emulsion and the lipid is in the form of lipid globules and the lipid globules are coated with protein, wherein the lipidcomprises 0.5 to 20 wt.% phospholipids by weight of total lipid, wherein the lipid globules have a mode diameter, based on volume, of less than 1 pm; and / or at most 40 vol.% of the lipid globules, based on total lipid volume, have a diameter of 2 to 12 pm.
[0031] By definition, the words “non-therapeutic” excludes any therapeutic effect.
[0032] Preferably, the increased lipid absorption is by a higher triglyceride secretion by the intestinal cells.
[0033] The use is for treating, preventing or reducing the effects of lipid malabsorption and / or disease related malnutrition, preferably disease related malnutrition. Diseases that cause lipid malabsorption are for example exocrine pancreatic insufficiency, chronic pancreatitis, Cystic fibrosis, Short Bowel Syndrome, or bile acid deficiency. Preferably, the use is for treating, preventing or reducing the effects of exocrine pancreatic insufficiency, chronic pancreatitis, Cystic fibrosis, Short Bowel Syndrome, or bile acid deficiency. More preferably, the use is for treating, preventing or reducing the effects of exocrine pancreatic insufficiency or bile acid deficiency.
[0034] The term “preventing” as used herein refers to stopping or reducing the incidence / severity of a disease, before the disease occurs.
[0035] Preferably, the increase of the lipid absorption by the intestinal cells is in comparison to the lipid absorption by the intestinal cells in a human subject who consumed a similar nutritional composition, as claimed, except that the lipid comprises less than 0.5 wt.% phospholipids by weight of total lipid.
[0036] In a preferred embodiment, the human subject is aged 0-36 months, more preferably 0-24 months, even more preferably 0-12 months and most preferably 0-6 months.
[0037] In an alternatively preferred embodiment, the human subject is a child >3 years to 18 years, or an adult of at least 18 years, more preferably the human subject is an adult of at least 18 years, and most preferably the human subject is an adult of at least 50 years.
[0038] Phospholipid
[0039] The lipid in the nutritional composition comprises 0.5 to 20 wt.% phospholipids based on total lipid. Preferably, the nutritional composition comprises 0.6 to 10 wt.%, more preferably 0.7 to 8 wt.%, even more preferably 0.8 to 6 wt.%, and most preferably 1 to 5 wt.% phospholipids based on total lipid.
[0040] Preferably at least 80 wt.% of the total phospholipids are located in the continuous phase of the oil-in-water emulsion, more preferably at least 85 wt.% of the total phospholipids and most preferably 90-100 wt.% of the total phospholipids are located in the continuous phase of the oil-in-water emulsion.Preferably, the nutritional composition comprises 0.1-1 g / L of phospholipids when the nutritional composition is in ready-to-drink format. More preferably the nutritional composition comprises 0.2-0.9 g / L of phospholipids, most preferably the nutritional composition comprises 0.3-0.8 g / L of phospholipids when the nutritional composition is in ready-to-drink format.
[0041] Phospholipids are amphipathic of nature and include glycerophospholipids and sphingomyelin.
[0042] The nutritional composition preferably comprises glycerophospholipids. Examples of glycerophospholipids are phosphatidylcholine (PC), phosphatidylserine (PS), phosphatidylethanolamine (PE), phosphatidylinositol (PI) and phosphatidylglycerol (PG). Preferably the nutritional composition comprises one or more of PC, PS, PI and PE, more preferably the nutritional composition comprises at least PC.
[0043] The nutritional composition preferably comprises sphingomyelin. Sphingomyelins have a phosphorylcholine or phosphorylethanolamine molecule esterified to the 1 -hydroxy group of a ceramide. They are classified as phospholipid as well as sphingolipid, but are not classified as a glycerophospholipid nor as a glycosphingolipid. Preferably the nutritional composition comprises 0.05 to 10 wt.% sphingomyelin based on total lipid, more preferably 0.1 to 5 wt.%, even more preferably 0.2 to 2 wt.%. Preferably the nutritional composition comprises at least 5 wt.%, more preferably 5 to 40 wt.% sphingomyelin based on total phospholipid, more preferably 10 to 35 wt.%, even more preferably 15 to 35 wt.% sphingomyelin, based on total phospholipid.
[0044] Preferred sources for providing the phospholipid are egg lipids, milk fat, buttermilk fat and butter serum fat (such as beta serum fat). Another preferred source for phospholipid, particularly PC, is soy lecithin and / or sunflower lecithin.
[0045] The nutritional composition preferably comprises phospholipid derived from mammalian milk. More preferably phospholipid derived from one or more mammalian milk(s) from cows, mares, sheep, goats, buffalos, horses and camels. Most preferably, the nutritional composition comprises phospholipid, derived from cow’s milk.
[0046] Phospholipid derived from mammalian milk preferably includes phospholipid derived from milk lipid, cream lipid, cream serum lipid, butter serum lipid (beta serum lipid), whey lipid, cheese lipid and / or buttermilk lipid. Buttermilk lipid is typically obtained during the manufacture of buttermilk. Butter serum lipid or beta serum lipid is typically obtained during the manufacture of anhydrous milk fat from butter. More preferably the phospholipid is derived from whey, e.g. a whey protein concentrate. Suitable commercially available sources for phospholipid from milk are BAEF, SM2, SM3 and SM4 powder of Corman, Salibra of Glanbia, Vivinal MFGM of FrieslandCampina and Lacprodan MFGM-10 or PL20 from Aria.Preferably the phospholipid is derived from mammalian milk, more preferably derived from or forms part of milk fat globule membrane (MFGM). More preferably, the phospholipids are derived from or forms part of cow’s MFGM.
[0047] In a preferred embodiment, the oil-in-water emulsion is prepared by a process comprising the steps of:
[0048] a) providing an aqueous phase with a dry matter content of 10 to 60 wt.% by weight of the aqueous phase, which comprises protein and digestible carbohydrates;
[0049] b) providing a liquid lipid phase, which comprises lipid;
[0050] c) emulsifying the aqueous phase of step a) with the lipid phase of step b) to obtain a first oil-in- water emulsion comprising less than 0.5 wt.% phospholipids by weight of total lipid;
[0051] d) mixing the first oil-in-water emulsion of step c) with a phospholipid composition, comprising at least 5 wt.% phospholipid by dry weight of said phospholipid composition, to obtain a second oil-in-water emulsion.
[0052] More preferably, the process further comprises:
[0053] e) drying the second oil-in-water emulsion of step d) to obtain a powdered nutritional composition; f) reconstituting the powdered nutritional composition with an aqueous liquid to obtain the oil-in- water emulsion.
[0054] Preferably, the nutritional composition for use is a powdered nutritional composition that is suitable for reconstitution to a liquid nutritional composition, more preferably the powdered nutritional composition is a powdered (or dried) version of the second oil-in-water emulsion in step d) in the aforementioned embodiment or the powdered nutritional composition of step e) in the aforementioned embodiment.
[0055] In an alternatively preferred embodiment, the oil-in-water emulsion is prepared by a process comprising the steps of:
[0056] a) providing a first powdered nutritional composition comprising lipid, protein, digestible and carbohydrates, wherein the powdered nutritional composition comprises less than 0.5 wt.% phospholipids by weight of total lipid;
[0057] b) providing a powdered phospholipid composition comprising at least 5 wt.% phospholipid by dry weight of the powdered phospholipid composition.
[0058] c) dry blending 90-99 wt. parts of the first powdered nutritional composition with 1-10 wt. parts of powdered phospholipid composition of step b) to obtain a second powdered nutritional composition; and
[0059] d) reconstituting the second powdered nutritional composition with an aqueous liquid to obtain the oil-in-water emulsion.
[0060] The phospholipid composition in the afore-mentioned preferred embodiments is preferably a milk-derived composition enriched in MFGM, more preferably a whey protein concentrate enriched in MFGM.Preferably, the nutritional composition for use is a powdered nutritional composition that is suitable for reconstitution to a liquid nutritional composition, more preferably the powdered nutritional composition is the second powdered nutritional composition from step c) in the aforementioned embodiment.
[0061] Lipid
[0062] The nutritional composition comprises lipid. The term “lipid” as used herein refers to one or more selected from the group consisting of triglycerides, polar lipids (such as phospholipids, cholesterol, glycolipids, sphingomyelin), free fatty acids, monoglycerides and diglycerides.
[0063] The lipid provides preferably 30 to 60% of the total calories of the nutritional composition. More preferably the nutritional composition comprises lipid providing 35 to 55% of the total calories, even more preferably the nutritional composition comprises lipids providing 40 to 50% of the total calories. The lipids are preferably present in an amount of 4 to 6 g per 100 kcal. When in liquid form, e.g. as a ready-to-feed liquid, the nutritional composition preferably comprises 2.1 to 6.5 g lipids per 100 ml, more preferably 3.0 to 4.0 g per 100 ml. Based on dry weight, the nutritional composition preferably comprises 10 to 50 wt.%, more preferably 12.5 to 40 wt.% lipids, even more preferably 19 to 30 wt.% lipids.
[0064] The lipid preferably comprises vegetable lipids. The presence of vegetable lipids advantageously enables an optimal fatty acid profile, high in polyunsaturated fatty acids. Lipids from mammalian milk alone, e.g. cow’s milk, do not provide an optimal fatty acid profile. The amount of essential fatty acids is too low in mammalian milk.
[0065] Preferably the nutritional composition comprises at least one, preferably at least two vegetable lipid sources selected from the group consisting of linseed oil (flaxseed oil), rape seed oil (such as colza oil, low erucic acid rape seed oil and canola oil), sunflower oil, high oleic sunflower oil, safflower oil, high oleic safflower oil, olive oil, coconut oil, palm oil and palm kernel oil.
[0066] In a preferred embodiment, the nutritional composition comprises 5 to 100 wt.% vegetable lipids based on total lipids, more preferably 10 to 95 wt.%, more preferably 20 to 80 wt.%, even more preferably 25 to 75 wt.%, most preferably 40 to 60 wt.% of vegetable lipids based on total lipids. Preferably, the nutritional composition also comprises non-vegetable lipids. Preferably, said non-vegetable lipids are one or more non-vegetable lipids selected from mammalian milk fat, mammalian milk derived lipid as a preferred source of phospholipid, and fish, marine and / or microbial oils as source of LC-PUFA.
[0067] Palmitic acid (PA) at sn-2 position of triglyceride
[0068] Triglycerides are preferably the major fraction of the lipids in the nutritional composition. Triglycerides comprise a glycerol moiety to which, via ester bonds, three fatty acid residues are attached, which may be the same or different, and which are generally chosen from saturated and unsaturated fatty acids containing 4 to 26 carbon atoms. Such triglycerides may differ in the fatty acid residues that are presentand / or may differ in the respective position(s) of the fatty acid residues to the glycerol backbone (e.g. in the sn-1 , sn-2 and / or sn-3 position).
[0069] Preferably, the nutritional composition comprises at least 70 wt.%, more preferably at least 80 wt.%, even more preferably at least 90 wt.% and most preferably at least 95 wt.% triglycerides based on total lipids.
[0070] Preferably, the lipid in the nutritional composition has a relatively low amount of palmitic acid (PA) located at the sn-2 position in a triglyceride, based on total PA. PA relates to palmitic acid and / or acyl chains (C16:0). The amount of palmitic acid (PA) that is present in the total lipid of the nutritional composition is preferably at least 10 wt.% based on total fatty acids, more preferably 12-30 wt.%, even more preferably 14 to 26 wt.% and most preferably 16 to 22 wt.% of PA by weight of total fatty acids. Preferably, at most 15 wt.% of PA, more preferably at most 10 wt.% of PA is in the sn-2 position in a triglyceride, based on total PA. So, preferably the lipid comprises at least 10 wt.% palmitic acid by weight of total lipid, and at most 15 wt.% of this palmitic acid is esterified to the sn-2 position of a triglyceride by weight of total palmitic acid.
[0071] In the context of the present invention, a weight percentage of fatty acids based on total fatty acids is calculated as if all fatty acids are free fatty acids, hence it is not taken into account whether a fatty acid is attached to a glycerol backbone or not.
[0072] Lipid globule size
[0073] The lipid is present in the nutritional composition in the form of lipid globules. When the nutritional composition is in liquid form, these lipid globules are emulsified in the continuous aqueous phase. Alternatively, when the nutritional composition is in powder form, the lipid globules are present in the powder and the powder is suitable for reconstitution with water or another food grade aqueous phase. The lipid globules comprise a core and a surface (alternatively termed ‘coating’).
[0074] The lipid globules in the nutritional composition have mode diameter, based on volume, of at most 1.0 pm, more preferably the lipid globules have a mode diameter, based on volume, between 0.1 and 0.9 pm, and most preferably between 0.2 and 0.8 pm.
[0075] Alternatively, or in addition, the size distribution of the lipid globules is preferably in such a way that at most 40 volume % (vol.%), more preferably at most 30 vol.%, and most preferably at most 20 vol.% of the lipid globules have a diameter between 2 and 12 pm.
[0076] The vol. percentage of lipid globules is based on volume of total lipid. The mode diameter relates to the diameter which is the most present based on volume of total lipid, or the peak value in a graphic representation, having on the X-axis the diameter and on the Y-axis the volume (%).The volume of the lipid globules and its size distribution can suitably be determined using a particle size analyzer such as a Mastersizer 2000 (Malvern Instruments, Malvern, UK), for example by the method described in Michalski et al, 2001 , Lait 81 : 787-796.
[0077] Digestible carbohydrates
[0078] The nutritional composition comprises digestible carbohydrates. The digestible carbohydrates preferably provide 30 to 80% of the total calories of the nutritional composition. Preferably the digestible carbohydrates provide 40 to 60% of the total calories. Based on calories the nutritional composition preferably comprises of 5 to 20 g of digestible carbohydrates per 100 kcal, more preferably 7.5 to 15 g. When in liquid form, e.g. as a ready-to-feed liquid, the nutritional composition preferably comprises 3 to 30 g digestible carbohydrate per 100 ml, more preferably 6 to 20 g, even more preferably 7 to 10 g per 100 ml. Based on dry weight, the nutritional composition preferably comprises 20 to 80 wt.%, more preferably 40 to 65 wt.% digestible carbohydrates.
[0079] Preferred digestible carbohydrate sources are lactose, glucose, sucrose, fructose, galactose, maltose, starch and maltodextrin. The nutritional composition preferably comprises lactose. The digestible carbohydrate comprises at least 50 wt.%, more preferably at least 75 wt.%, and most preferably at least 95 wt.% of lactose.
[0080] Protein
[0081] The nutritional composition comprises protein. The protein preferably provides 5 to 15% of the total calories, more preferably 6 to 12% of the total calories. Preferably protein is present in the nutritional composition below 3.5 gram per 100 kcal, more preferably between 1.8 and 2.1 g protein per 100 kcal, and most preferably between 1.85 and 2.0 g protein per 100 kcal. The protein concentration in a nutritional composition is determined by the sum of protein, peptides and free amino acids. Based on dry weight, the nutritional composition preferably comprises less than 12 wt.% protein, more preferably between 9.6 and 12 wt.%, most preferably between 10 and 11 wt.% protein. Based on a ready-to-drink liquid product the nutritional composition preferably comprises less than 1.5 g protein per 100 ml, more preferably between 1.2 and 1.5 g, even more preferably between 1.25 and 1.35 g protein per 100 ml.
[0082] The source of the protein is preferably selected in such a way that the minimum requirements for essential amino acid content are met. Hence protein sources based on cows' milk proteins such as whey, casein and mixtures thereof and proteins based on soy, potato or pea are preferred. Preferably the protein in the nutritional composition is dairy protein, such as casein and whey protein.
[0083] Application
[0084] The nutritional composition is preferably selected from infant formula, follow-on formula and young child formula. More preferably, the nutritional composition is an infant formula or a follow-on formula. Most preferably, the nutritional composition is an infant formula.The terms as used herein, “infant formula” or “follow-on formula” or “young child formula” refers to compositions that are artificially made or that are synthetic. This means that the composition that is administered is not human milk. It also means that the administered composition is not native cow’s milk or native milk from another mammal.
[0085] In the present context, infant formula refers to nutritional compositions, artificially made, intended for infants of 0 to about 4 to 6 months of age and are intended as a substitute for human milk. Typically, infant formulae are suitable to be used as sole source of nutrition. Such formulae are also known as starter formula. Formula for infants starting for 4 to 6 months of life to 12 months of life are intended to be supplementary feedings to infants that start weaning on other foods. Such formulae are also known as follow-on formulae. Infant formulae and follow-on formulae are subject to strict regulations, for example the EU regulations no. 609 / 2013 and no. 2016 / 127. In the present context, young child formulae refers to nutritional compositions, artificially made, intended for infants of 12 months to 36 months, which are intended to be supplementary feedings to infants. Such formulae are also known as growing-up milks.
[0086] The nutritional composition is preferably an infant formula or follow-on formula and preferably comprises 3 to 7 g lipid / 100 kcal, preferably 4 to 6 g lipid / 100 kcal, more preferably 4.5 to 5.5 g lipid / 100 kcal, preferably comprises 1.7 to 5 g protein / 100 kcal, more preferably 1.8 to 3.5 g protein / 100 kcal, even more preferably 1.8 to 2.1 g protein / 100 kcal, most preferably 1.8 to 2.0 g protein / 100 kcal and preferably comprises 5 to 20 g digestible carbohydrate / 100 kcal, more preferably 6 to 16 g digestible carbohydrate / 100 kcal, and most preferably 10 to 15 g digestible carbohydrate / 100 kcal.
[0087] Preferably the nutritional composition is an infant formula or follow-on formula and when in a ready-to-drink format has an energy density of 60 kcal to 75 kcal / 100 ml, more preferably 60 to 70 kcal / 100 ml. This density ensures an optimal balance between hydration and caloric intake.
[0088] In an alternatively preferred embodiment the nutritional composition is a medical nutritional product, preferably a medical nutritional product for human subjects suffering from lipid malabsorption and / or disease-related malnutrition.
[0089] In the context of the invention, the terminology “increasing lipid absorption”, means increasing the lipid absorption compared to the lipid absorption obtained for a conventional infant formula. In one embodiment, such a conventional infant formula has similar nutritional profile except that the lipid comprises less than 0.5 wt.% phospholipids by weight of total lipid.
[0090] In a separate embodiment, the nutritional composition is administered to healthy subjects. When administered to healthy subjects the lipid absorption by intestinal cells in the human subject is increasedand confers non-therapeutic benefits. An increased lipid absorption in healthy subjects results in a balanced lipid metabolism and contribute to an increased nutritional efficiency.
[0091] In this document and in its claims, the verb “to comprise” and its conjugations is used in its non-limiting sense to mean that items following the word are included, but items not specifically mentioned are not excluded. In addition, reference to an element by the indefinite article “a” or “an” does not exclude the possibility that more than one of the element is present, unless the context clearly requires that there be one and only one of the elements. The indefinite article “a” or “an” thus usually means “at least one”.
[0092] EXAMPLES
[0093] Example 1
[0094] Test compositions
[0095] Two infant formulas (IFs) were prepared: IF1 and IF2. Both IF1 and IF2 were produced according to a standard production process as is known in the art for producing infant formula. They both comprised the same energy content, dry matter content (13.6 g / 100 ml) and volume weighed mode diameter of the lipid globules. In both formula’s the lipid globules were coated with dairy protein.
[0096] The macronutrient content of both IF1 and IF2 was similar to standard formulas in the art, and both comprised about 1.3 g protein per 100 ml, 7.4 g carbohydrate per 100 ml, and 3.4 g lipid per 100 ml. The source of lipid was a vegetable lipid mixture of rapeseed, sunflower, coconut, and palm oil, and LC-PUFA containing oil (fish oil and microbial oil). The fatty acid profile was similar for both IF1 and IF2 and both comprised about 19.8 g palmitic acid 1 100g fatty acid. As the palmitic acid is provided by a vegetable lipid source, the palmitic acid is predominantly present in the sn-1 ,3 position of a triglyceride.
[0097] IF2 is an infant formula with a similar composition as IF1 , but in addition comprising milk-derived phospholipids. IF2 included a whey protein concentrate enriched in MFGM (Lacprodan MFGM-10, Aria), which provided milk-derived phospholipids (about 1.5 wt.% based on total lipid of IF2). The added phospholipid component was not present in the coating of the lipid globules, but was present as a free component in the continuous phase of the infant formula.
[0098] A suitable way to determine the volume of lipid globules and their size distribution is by using a Mastersizer 2000 (Malvern Instruments, Malvern UK), for example by the method described in Michalski et al, 2001 , Lait 81 : 787-796. A refractive index (Rl) of 1.46 (approximate Rl of milk fat in water) was used for particle size determination and the specific surface area was determined by the apparatus.The lipid globules in IF1 and IF2 have the same mode diameter based on volume of about 0.3-0.5 pm, and less than 40 vol. % of the lipid globules had a diameter between 2 to 12 pm. The specific surface area in m2 / g lipid was about 25.
[0099] Simulated digestion protocol
[0100] Infant formulas IF1 and IF2 were reconstituted by dispersing 13.6 g powdered IF product in luke-warm demineralized water and by shaking until dispersed.
[0101] Simulated infant digestion was performed as described in Abrahamse, et al., Gastrointestinal Protein Hydrolysis Kinetics: Opportunities for Further infant formula improvement. Nutrients, 2022. 14(7), with an adapted simulated gastric fluid (SGF, 16.6 mg I mL - 100 U I mL RGE.340, 3.1 g / L NaCI, 1.1 g / L KCI, 0.15 g / L CaCh 2H2O, 0.82 g / L Na-acetate). 36.5 ml of reconstituted IF was placed in a computer controlled parallel fed-batch reactor (Eppendorf, Dasgip Mini Spinner Type DS0100B, Eppendorf Nederland BV, Nijmegen, the Netherlands) at 37°C . Over a 5 min period, the pH was equilibrated to 6.8 by addition of acid (0.25M HCI) or base (0.25M NaHCOs, 0.25M NaOH). After equilibration, gastric digestion was simulated (120 min Gastric phase). 5.8 mL of simulated saliva fluid was added, 12.3 mL of the adapted simulated SGF was gradually added and the pH was gradually lowered to 4.3. Following the gastric phase, the pH was neutralized over the course of 10 min. Intestinal digestion was simulated for 120 min with the gradual addition of 21 mL of simulated intestinal fluid (SIF) during the first hour, then 25 mL of the reactor content was taken and aliquoted in 1 mL portions, snap frozen and stored at -80 °C for incubation on intestinal cells (I60 min sample).
[0102] Free fatty acids (FFA) were quantified by gas chromatography in the I60 min sample.
[0103] Incubation with Caco-2 cells
[0104] A human Caco-2 cell line was used as a model of intestinal epithelium and was provided by Dr M. Rousset (Inserm, Paris, France). Caco-2 / TC7 intestinal cells undergo spontaneous differentiation that leads to a cell monolayer formation expressing several morphological and functional characteristics of enterocytes. Among Caco-2 cells, the TC7 clone has been described to be the most relevant for FA absorption studies.
[0105] Cells were routinely cultured in high-glucose (4.5g / L) medium with glutamine (DMEM GlutaMAX; Invitrogen, Thermo Fisher Scientific) supplemented with 20% foetal calf serum, 1% of non-essential amino acids and 1% penicillin / streptomycin, maintained under a 10% CO2 atmosphere at 37 °C and were used between passages 38 and 43. After reaching 80% confluence, cells were detached with trypsin and seeded on permeable Transwell® filter inserts at a density of 5 x104cells / cm2(24 mm insert, 0.4 mm pore size Polyester membrane, Corning Costar) in 6-well plates to reproduce the polarized intestinal epithelium. This enabled the establishment of an apical (upper) compartment mimicking the intestinal lumen and a basolateral (lower) compartment mimicking the portal and lymphatic circulation.Cells were grown to confluence in complete medium for one week then cultured in asymmetric conditions, with 2 mL medium containing foetal calf serum in the lower compartment and 1.5 mL serum-free medium in the upper compartment until total differentiation (around 21 days after seeding). The medium was changed every 2-3 days.
[0106] First, apical incubation with digested IF diluted (10xto 80x) in serum-free complete medium was tested to find the dilution factors that ensure both an absence of toxicity on the Caco-2 / TC7 cells and a measurable triglyceride secretion.
[0107] For the incubation on the intestinal cells of the I60 min samples, the I60 min samples were diluted (IF1 : 23.4x, IF2: 22.8x) to achieve equimolar FFA concentrations of 1.3 mM, and were applied (1.5 ml) to the apical compartment of the Caco-2 / TC7 cells for 16 h (n=4). Basolateral contents were sampled after incubation and these samples were stored at -80 °C, until analysis forTG content.
[0108] Triglyceride secretion in the basolateral medium reflects the extent of lipid absorption by this cell model. It was measured by Fluometric Triglyceride Assay Kit, Abeam.
[0109] Intracellular lipid droplets were stained by Oil Red O (Sigma Aldrich) and were quantified after acquiring 10 images per well by standard light microscopy. Using Imaged software (U.S. National Institutes of Health) the contrast was enhanced by 0.1% in order to better distinguish smallest droplets. Quantification was then performed by selecting and counting pixels with a saturation larger than 140 with the Otsu thresholding method. Segmentation was then applied automatically using the Watershed method of Imaged in order to count and measure lipid droplets individually.
[0110] Results
[0111] CLD I chylomicron amount and size in the Caco-2 cells after 16h incubation with digested IF’s was quantified. There were no differences between the IF’s at 16h in the amounts of lipid droplets I chylomicrons, however, the mean droplet area tended to be statistically significantly larger (p=0.044, Student’s t-test) for IF2 (12.18 ± 1.35 pm2) versus IF1 (10.14 ± 0.86 pm2).
[0112] Absorption of FA from the apical to basolateral sides of the intestinal cells was quantified over 16h. At 16h triglyceride secretion was statistically significantly increased (p=0.0016, Student’s t-test) in IF2 (0.17 ± 0.02 mM) compared to IF1 (0.09 ± 0.02 mM).
[0113] This is indicative for an increased rate of lipid absorption in the intestinal cells of a human subject, which may have beneficial effects on lipid malabsorption, disease related malnutrition and related diseases of the gastrointestinal tract.
Claims
CLAIMS1. A nutritional composition comprising lipid, protein, digestible carbohydrates, wherein the nutritional composition is an oil-in-water emulsion and the lipid is in the form of lipid globules and the lipid globules are coated with protein, wherein the lipid globules have a mode diameter, based on volume, of less than 1 pm; and / or at most 40 vol.% of the lipid globules, based on total lipid volume, have a diameter of 2 to 12 pm, wherein the lipid comprises 0.5 to 20 wt.% phospholipids by weight of total lipid, wherein the composition is for use in increasing the lipid absorption by intestinal cells in a human subject, wherein the use is for treating, preventing or reducing the effects of lipid malabsorption and / or disease related malnutrition.
2. The nutritional composition for use according to claim 1 , wherein the increased lipid absorption is by a higher triglyceride secretion by the intestinal cells.
3. The nutritional composition for use according to claim 1 or 2, wherein the use is for treating, preventing or reducing the effects of exocrine pancreatic insufficiency or bile acid deficiency.
4. The nutritional composition for use according to any one of the previous claims, wherein at least 80 wt.% of the total phospholipids are located in the continuous phase of the oil-in-water emulsion.
5. The nutritional composition for use according to any one of the previous claims, wherein the phospholipids are mammalian milk-derived phospholipids, preferably the phospholipids are derived from or form part of milk fat globule membrane (MFGM).
6. The nutritional composition for use according to any one of the previous claims, wherein at least 90wt.% of the coating of the lipid globules is protein, preferably dairy protein.
7. The nutritional composition for use according to any one of the previous claims, wherein the lipid comprises at least 10 wt.% palmitic acid by weight of total lipid, and at most 15 wt.% of this palmitic acid is esterified to the sn-2 position of a triglyceride by weight of total palmitic acid.
8. The nutritional composition for use according to any one of the previous claims, wherein the oil-in-water emulsion is prepared by a process comprising the steps of:a) providing an aqueous phase with a dry matter content of 10 to 60 wt.% by weight of the aqueous phase, which comprises protein and digestible carbohydrates;b) providing a liquid lipid phase, which comprises lipid;c) emulsifying the aqueous phase of step a) with the lipid phase of step b) to obtain a first oil-in-water emulsion comprising less than 0.5 wt.% phospholipids by weight of total lipid;d) mixing the first oil-in-water emulsion of step c) with a phospholipid composition, comprising at least 5 wt.% phospholipid by dry weight of said phospholipid composition, to obtain a second oil-in-water emulsion.
9. The nutritional composition for use according to any one of claims 1-7, wherein the oil-in-water emulsion is prepared by a process comprising the steps of:a) providing a first powdered nutritional composition comprising lipid, protein, digestible and carbohydrates, wherein the powdered nutritional composition comprises less than 0.5 wt.% phospholipids by weight of total lipid;b) providing a powdered phospholipid composition comprising at least 5 wt.% phospholipid by dry weight of the powdered phospholipid composition.c) dry blending 90-99 wt. parts of the first powdered nutritional composition with 1-10 wt.parts of powdered phospholipid composition of step b) to obtain a second powdered nutritional composition; andd) reconstituting the second powdered nutritional composition with an aqueous liquid to obtain the oil-in-water emulsion.
10. The nutritional composition for use according to claim 8 or 9, wherein the nutritional composition is a powdered nutritional composition that is suitable for reconstitution to a liquid nutritional composition, wherein the powdered nutritional composition is selected from a powdered version of the second oil-in-water emulsion from step d) in claim 8 or the second powdered nutritional composition from step c) in claim 9.
11. The nutritional composition for use according to any one of the previous claims, wherein the increase of the lipid absorption by the intestinal cells is in comparison to the lipid absorption by the intestinal cells in a human subject who consumed a similar nutritional composition except that the lipid comprised less than 0.5 wt.% phospholipids by weight of total lipid.
12. The nutritional composition for use according to any one of the previous claims, wherein the nutritional composition is selected from infant formula, follow-on formula, or growing up milk.
13. The nutritional composition for use according to any one of claims 1-11 , wherein the nutritional composition is a medical nutritional product.
14. Non-therapeutic method for increasing lipid absorption by intestinal cells in a human subject, comprising administering a nutritional composition comprising lipid, protein, digestiblecarbohydrates, wherein the nutritional composition is an oil-in-water emulsion and the lipid is in the form of lipid globules and the lipid globules are coated with protein, wherein the lipid comprises 0.5 to 20 wt.% phospholipids by weight of total lipid, wherein the lipid globules have a mode diameter, based on volume, of less than 1 pm; and / or at most 40 vol.% of the lipid globules, based on total lipid volume, have a diameter of 2 to 12 pm.
